Form 4: Director Marshall Mohr Receives PACB Stock Option Grant

Pacific Biosciences director Marshall Mohr was granted an option to purchase 223,492 shares of common stock.

Summary

• Director Marshall Mohr received a grant of 223,492 stock options on June 3, 2026.
• The options have an exercise price of $1.58 per share.
• The options vest monthly over a one-year period, contingent on continued service as a director.
• The options expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Dependence on continued director service for the vesting of the granted options.

Future Outlook

The options vest monthly over one year, provided the director remains in service, aligning the director's tenure with company performance through 2027.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members are incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The one-year vesting schedule is consistent with standard director compensation packages for mid-cap biotech firms.
• The grant size is typical for board-level equity compensation in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential minor dilution upon exercise of options.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of options to commence on July 3, 2026.

Key Dates

Keywords

Pacific Biosciences, PACB, Form 4, Insider Trading, Stock Options, Marshall Mohr